 Marta New, Ph.D., MBA |
Interview with Marta New, founder and CEO of Radyus Research
By Caitlin Dolegowski, Marketing Manager, LSN |
 Caitlin Dolegowski |
Caiti Dolegowski (CD): Introduce us to Radyus Research.
Marta New (MN): Radyus Research is a fully integrated, one-stop, preclinical drug-development CRO for small molecules, peptides, and antibodies. We created Radyus after seeing a need for a different approach to drug development that is more custom and personal to each client’s needs.
We work with biotech companies, academic startups, and venture capital firms developing preclinical assets ranging from drug discovery and lead candidate selection to lead optimization and IND-enabling studies.
Our business is designed to function in a way that views a holistic picture of our client’s needs, creating long-term partnerships instead of one-off projects. This kind of working design has allowed us to build an incredibly skilled and diverse team to help our clients reach their goals and even help create their next goal.
CD: Radyus Research has over 150 years of work experience in the development of therapeutics. Tell us about your team and their fields.
MN: First, I am very proud of our team and how we built it. We have taken special care to form a team of industry experts that can offer something unique to the world of drug development. Our team members come from big pharma, venture capital, CROs, and consulting. With such a diverse group, we can identify issues and opportunities that others may not. We have found that the unique combination of experience and expertise we have in place makes it easier for our clients to rely on us to help take their drug to IND because we know what buyers are looking for.
That 150 years of combined experience you mentioned comes from our team developing therapeutics in the fields of oncology, immunology, neuro/CNS, respiratory, metabolic, and infectious diseases. We provide scientific expertise, strategic guidance, and even operational implementation.
But it is not just the expertise of our team members that makes us a one-stop shop for preclinical drug development; it is also our philosophy of partnership and problem-solving. The diverse capabilities of our team allow us to work as a true extension of our clients, discovering new pathways forward they might not uncover on their own.
We’re also beginning team spotlight posts exclusively on LinkedIn that will introduce our amazing team members to the drug-development community. I encourage everyone to follow our LinkedIn page to learn more about our team.
CD: What type of client is your ideal fit?
MN: We work with smaller venture-backed biotech companies that typically have a relatively small employee count and are in the early stages of development, and mid-sized venture-backed biotech companies with a moderate employee base and strong financial resources. We also work with Venture Capital Funds doing new company formation.
CD: Radyus Research is a sponsor at RESI, and we’re excited to have you as a part of our RESI community. Radyus hosted a workshop at RESI Boston June, Maximizing Preclinical Development Success for VC-Backed Startups Through CRO Partnerships. What did RESI attendees learn during this workshop?
MN: We are certainly excited to partner with RESI and put on this workshop. In the workshop, we discussed the value of strategic planning, efficient collaboration, and effective project management in drug development and what should be expected from each.
We also discussed a few of the steps needed to maximize success, like how to define clear objectives, selecting the right CRO partner, developing a comprehensive project and management plan, how to ensure quality and compliance during the project, and the best way to evaluate project performance and learn. We talked through some ways to manage resources and how to foster a collaborative relationship to increase the chances of maximizing preclinical development success.
CD: I joined the panelist planning call for your workshop and noticed a theme of personalized service. Why is that important to Radyus Research and what does it mean for your clients?
MN: Personalized service is the game-changer. We have learned that having a truly tailored approach requires more than defined actions only. It is a mindset that must permeate the entire team. Each drug development project is unique, with specific goals, timelines, and requirements. Viewing each client as a unique relationship allows us to customize our support to fit the specific needs of the VC-backed biotech companies we work with. Here are three reasons our focus is always on developing a partnership first:
- Ability to adapt: A tailored approach allows for unique flexibility and agility when adapting to the evolving needs of each client’s preclinical development project. We can quickly adjust to new strategies, resources, or timelines to address challenges.
- A Higher level of support: Because we work as an extension of our client’s team, there is a direct line of communication and collaboration. This allows for more efficient knowledge transfer, timely guidance, and proactive problem-solving. We are more familiar with specific goals, approaches, and strategic priorities because, in many cases, we work with our clients to set each of these from the start.
- Attention to Detail: The level of client integration we practice emphasizes attention to detail and a focus on quality, reducing the risk of errors or oversights that could compromise success. Our clients will always work with our “A-team,” who will be engaged and know the project from start to finish to creation of next steps.
Next Phase Newsletter 